BioPharma Resources

Drug Trial Radar · NCT07096791

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of KH607 in the Treatment of Adult Female Participants With Postpartum Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Sep 2, 2025

Primary completion

Apr 24, 2026

Study completion Apr 24, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study evaluating the efficacy, and safety of KH607 in 72 participants diagnosed with Postpartum Depressive Disorder.

Conditions

  • Postpartum Depressive Disorder

Interventions

  • KH607 tabletDrug

    oral,once daily for 14 days

  • placeboDrug

    oral,once daily for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D17) Total Score at Day 15Time frame: Baseline, Day15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • BeiJing AnDing Hospital capital medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.